Clinical Trials Logo

Clinical Trial Summary

The TQB2868 protein in this study targeted programmed cell death protein 1 (PD-1) and transforming growth factor-β (TGF-β). The bifunctional fusion protein targets and neutralizes TGF-β in the tumor microenvironment. On the basis of inhibiting PD-1 / programmed death ligand 1 (PD-L1) pathway, T cells can restore activity, enhance immune response, and more effectively improve the effect of inhibiting tumor occurrence and development.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05198505
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Caicun Zhou, Doctor
Phone 18796218833
Email caicunzhoudr@163.com
Status Recruiting
Phase Phase 1
Start date April 27, 2022
Completion date June 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05015309 - A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT06022250 - The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor Phase 1
Recruiting NCT06059508 - Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05851092 - Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors Phase 1
Suspended NCT05089461 - A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor Phase 2
Active, not recruiting NCT04296994 - A Study of QL1706 in Subjects With Advanced Malignant Tumor Phase 1
Recruiting NCT05416359 - Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT04954456 - A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies Phase 1
Recruiting NCT04326829 - QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors Phase 2
Recruiting NCT04739111 - An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor Phase 1
Recruiting NCT05767060 - BAT7104 Injection in Patients With Advanced Malignant Tumors. Phase 1
Recruiting NCT04975204 - A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors Phase 1
Recruiting NCT05144061 - A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors Phase 1
Completed NCT05042908 - Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies Phase 1
Recruiting NCT04412564 - A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor Phase 2
Not yet recruiting NCT05318833 - A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors Phase 1